论文部分内容阅读
目的评价头孢西丁与左氧氟沙星治疗成人非重症社区获得性肺炎(CAP)的成本-效果。方法回顾性选择2014年6月至2015年12月进行治疗的126例成人非重症CAP患者,将其随机分为头孢西丁组和左氧氟沙星组,每组63例。头孢西丁组患者静脉滴注头孢西丁钠,2.0 g/次,3次/d,8 d为1个疗程;左氧氟沙星组患者静脉滴注甲磺酸左氧氟沙星注射液,200 ml/次,1次/d,8 d为1个疗程。比较两组患者1个疗程后的临床治疗效果、显效时间、治疗成本、不良反应的发生情况,且进行成本-效果评价。结果左氧氟沙星组患者的总有效率为87.30%,显著高于头孢西丁组(63.49%,P<0.05);头孢西丁组患者的显效时间为(5.61±2.95)d,左氧氟沙星组为(3.65±2.66)d,两组比较差异有统计学意义(P<0.05);两组不良反应比较差异未见统计学意义(P>0.05)。头孢西丁组成本为8 513.20元,成本-效果为134.09,增量成本效果比为-59.85;左氧氟沙星组成本为7 080.52元,成本-效果为81.11,增量成本效果比为0。结论左氧氟沙星治疗成人非重症CAP的经济性更好。
Objective To evaluate the cost-effectiveness of cefoxitin and levofloxacin in the treatment of adults with non-critically ill community-acquired pneumonia (CAP). Methods A total of 126 adult patients with non-severe CAP who were treated from June 2014 to December 2015 were retrospectively selected and randomly divided into cefoxitin group and levofloxacin group, with 63 cases in each group. Cefoxitin group patients intravenous cefoxitin sodium, 2.0 g / times, 3 times / d, 8 d for a course of treatment; levofloxacin intravenous infusion of levofloxacin mesylate group, 200 ml / time, 1 / d, 8 d for a course of treatment. Two groups of patients after a course of treatment of clinical efficacy, effective time, treatment costs, the incidence of adverse reactions, and cost-effectiveness evaluation. Results The total effective rate of levofloxacin group was 87.30%, significantly higher than that of cefoxitin group (63.49%, P <0.05). The effective time of cefoxitin group was (5.61 ± 2.95) days and that of levofloxacin group was (3.65 ± 2.66) d, the difference between the two groups was statistically significant (P <0.05); no significant difference between the two groups was statistically significant (P> 0.05). The cost of cefoxitin was 8 513.20 yuan, the cost-effectiveness was 134.09, the cost-effectiveness ratio was -59.85, the cost of levofloxacin was 7080.52 yuan, the cost-effectiveness was 81.11, and the cost-effectiveness ratio was 0. Conclusion Levofloxacin is more economical to treat adult non-severe CAP.